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Here we elucidated the pathogenesis of a 14-year-old Chinese female who initially developed an 
isolated nephropathy followed by a complex clinical presentation with brain and muscle problems, 
which indicated that the disease process was possibly due to a mitochondrial dysfunction. Careful 
evaluation of renal biopsy samples revealed a decreased staining of cells induced by COX and 
NADH dehydrogenase activities, and a strong fragmentation of the mitochondrial network. These 
anomalies were due to the presence of a mutation in the mitochondrial ATP6 gene, G8969>A. This 
mutation leads to replacement of a highly conserved serine residue at position 148 of the a-subunit 
of ATP synthase. Increasing the mutation load in cybrid cell lines was paralleled by the appearance of 
abnormal mitochondrial morphologies, diminished respiration and enhanced production of reactive 
oxygen species. An equivalent of the G8969>A mutation in yeast had dramatic consequences on ATP 
synthase, with a block in proton translocation. The mutation was particularly abundant (89%) in the 
kidney compared to blood and urine, which is likely the reason why this organ was affected first. Based 
on these findings, we suggest that nephrologists should pay more attention to the possibility of a 
mitochondrial dysfunction when evaluating patients suffering from kidney problems.
Mitochondrial dysfunction has been implicated in a broad spectrum of human diseases, often referred to as 
mitochondrial cytopathies (MCs). These diseases affect at least 1 in 5,000 live human births1, and can present 
either in infancy or adulthood, in a multi-systemic or highly tissue-specific manner. Typical clinical traits include 
visual/hearing defects, encephalopathies, cardiomyopathies, myopathies, diabetes, liver and renal dysfunctions2,3. 
Most of the known (> 150) mitochondrial dysfunction genetic syndromes that have been described arise from 
disorders affecting oxidative phosphorylation, which is a mitochondrial process that provides cellular energy by 
generating ATP molecules.
The energy-transducing system of mitochondria comprises multi-subunit complexes (I-V) embedded within 
the mitochondrial inner membrane, which together with cytochrome c and ubiquinone, form what is usually 
called the OXPHOS system4. CI-IV transfer electrons to oxygen, a process that is coupled to the pumping of pro-
tons out of the mitochondrial matrix; protons are transported back into the matrix by CV (ATP synthase), which 
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is coupled to ATP synthesis from ADP and inorganic phosphate. The OXPHOS system has a mixed genetic origin, 
nuclear and mitochondrial. It contains approximately 90 different structural protein subunits of which thirteen 
are encoded by the mtDNA in humans5.
We here report a Chinese girl who was admitted to hospital at the age of 14 for a severe IgA nephropathy. 
This is a common glomerulonephritis typically affecting young adults that can also occur in children and the 
elderly. The disease has a wide spectrum of clinical symptoms, ranging from asymptomatic microscopic hema-
turia to a more severe course characterized by sustained proteinuria and rapid deterioration of renal function6. 
Unexpectedly, our patient further developed a more complex clinical presentation with brain and muscle prob-
lems, indicating that the disease had possibly a mitochondrial origin. We indeed found that a mutation in the 
mtDNA that dramatically compromises mitochondrial ATP production contributed to the disease process.
Results
Case report. The patient was admitted at the age of 14 to the hospital due to a nephrotic syndrome charac-
terized by the presence of high levels of red blood cells and protein in urine, and edema. A complete remission 
was observed after treatment with steroids, but she relapsed two years later. Following readmission, a renal biopsy 
was taken and shown to have almost normal glomeruli with only mild mesangial widening, whereas segmen-
tal tubular epithelial cells were flat and the interstitium between tubules were abnormally enlarged (Fig. 1A). 
Immunofluorescence analyses revealed the presence of immunoglobulin A (IgA) deposits in the kidney, a typical 
sign of IgA nephropathy (Fig. 1B)6. Further evidence for kidney alteration was provided by electron microscopy, 
which revealed podocyte foot process fusion in glomeruli, the presence of electron-dense deposits in the glomer-
ular mesangium, and brush border loss in focal tubules (Fig. 1C, see ref. 7 for electron micrographs of healthy 
kidney tissues).
The patient was treated again with steroids and entered remission for a second time. However, two years 
later renal impairment reoccurred and the patient was hospitalized once more for serious edema and very low 
urine output (oliguria). Meanwhile, she showed epileptic episodes and decreased muscle strength, brain atrophy, 
severe hearing impairment, Wolff-Parkinson-White syndrome, and increased fasting level of glucose (11.09 mM 
vs 3.6 mM for the control).
Hints for mitochondrial dysfunction. Mitochondria in tubular epithelial cells of the patient had a rather 
spherical contour whereas they were much more elongated in control cells (Fig. 1D), indicating an enhanced 
fragmentation of the mitochondrial network. Histochemical analyses of fresh renal biopsies further revealed that 
cytochrome c oxidase (COX) and nicotinamide adenine dinucleotide (NADH) dehydrogenase activities were 
substantially decreased in the patient compared to the control (Fig. 1E, Supplementary Fig. S1). We additionally 
detected a pronounced peak of lactate in cerebrospinal fluid from the patient (Supplementary Fig. S2) which 
indicated a less efficient oxidation of pyruvate (the oxidized form of lactate) in mitochondria.
These observations suggested that a mitochondrial dysfunction was possibly at the origin of, or contributed 
to, the disease process. This led us to analyze the mtDNA of the patient. No visible rearrangement (deletion) 
(Fig. 2A) and depletion (Fig. 2B) were observed. However, a point mutation (G8969> A) that was absent in 2704 
controls in databases as well as in 100 age-matched controls from the same geographic region, was detected in 
the ATP6 gene (Fig. 2C, Supplementary Table S3). This mutation leads to the replacement of a serine residue by 
asparagine at position 148 in the a-subunit of ATP synthase (aS148). This residue strictly conserved in mitochon-
dria and bacteria (see below).
Pyrosequencing analysis revealed that the G8969> A mutation was heteroplasmic in blood, urine sediments 
(epithelial-like cells detached from tubules) and kidney, with loads ranging from 60 to 90% respectively (Fig. 2D). 
The G8969> A mutation was also detected in blood and urine sediments from the mother, indicating that the 
mutation was maternally inherited. It was however in lower amounts in the mother (< 60%, Fig. 2D), which may 
explain that she was free of symptoms. It is indeed well known that mtDNA mutations become deleterious for 
health only beyond a certain threshold8, usually above 70% in the case of ATP6 mutations9.
Properties of cybrid cell lines containing various proportions of the G8969>A mutation. To 
further define the pathogenesis of the G8969> A mutation, cybrid cell lines containing various proportions of 
this mutation (19%, C-19; 67%, C-67; and 98%, C-98) were constructed (Fig. 3A). This is a common strategy used 
to ascertain that a disease is linked to mitochondrial DNA10. Increasing the G8969> A mutation load was paral-
leled by changes in the ultrastructure of mitochondria, with the appearance of torus-like and horseshoe-shape 
mitochondria with only a few or a single cristae present (Fig. 3B). Oxygen consumption was decreased in the 
mutated cybrid cells lines and the residual respiration was poorly inhibited by oligomycin, a specific inhibitor of 
ATP synthase (Fig. 3C). Respiration was also decreased in the mutant cybrid cells compared to the control in the 
presence of the proton ionophore carbonylcyanide p-trifluoromethoxyphenylhydrazone (FCCP), indicating a 
reduced content of some of the enzymes involved in electron transfer to oxygen. Finally, increasing the mutation 
load was paralleled by higher levels of reactive oxygen species (ROS) (Fig. 3D). All these defects are typically 
observed in cells with a defective ATP synthase11–16.
Consequences of the G8969>A mutation in yeast. To understand how the G8969> A mutation 
molecularly impacts ATP synthase, a yeast model of this mutation was created. The S148 residue of the human 
a-subunit corresponds to S175 of the yeast protein (referred to as subunit-6). As yeast is unable to stably maintain 
heteroplasmy17, it was possible to generate homoplasmic strains in which all the mtDNA molecules contain the 
atp6-S175N mutation, which enabled a detailed investigation of the functional consequences of this mutation. We 
found that the atp6-S175N mutation virtually abolished the growth of yeast on non-fermentable carbon sources 
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like glycerol (Fig. 4A), conditions under which the presence of a functional ATP synthase is absolutely essential. 
To determine the impact of the atp6-S175N mutation on oxidative phosphorylation, mitochondria were isolated 
from the cells grown in rich galactose medium and analyzed as described hereafter.
Respiration. We first measured mitochondrial oxygen consumption using NADH as an electron donor, alone 
(basal, state 4 respiration), after further addition of ADP (state 3, phosphorylating conditions) or in the presence 
of the membrane proton ionophore CCCP (carbonyl cyanide m-chlorophenylhydrazone) (uncoupled respiration) 
(Fig. 4B, Supplementary Table S4). In all these conditions, respiration was strongly decreased in the atp6-S175N 
mutant, by about 90% with respect to the WT. These findings were an indication that the mutation severely com-
promised ATP synthase. Indeed yeast mutants with a defective ATP synthase often respire poorly18–22.
ATP synthesis/hydrolysis. We measured the rate of mitochondrial ATP synthesis using NADH as a respiratory 
substrate and in the presence of a large excess of external ADP. In these conditions, ATP is synthesized only by 
Figure 1. Kidney defects in the patient. (A) Light microscopy of kidney cells shows minimal change disease 
(MCD) in glomeruli (G) and tubular lumen (TL) dilatation in the patient. (B) Fluorescence microscopy shows 
IgA deposits in kidney cells (vs black balanced control cells). (C) Electron micrographs showing podocyte foot 
process fusion in glomeruli (left, ↑ ), electron-dense deposits in the glomerular mesangium (white arrows) and 
brush border loss in focal tubules (right, ↑ ). (D) Ultrastructure of mitochondria (m) in tubular epithelial cells 
from the patient and a control individual. (E) In situ cytochrome c oxidase (COX) and NADH dehydrogenase 
activities in renal tissue from the patient and a control individual.
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ATP synthase using the proton-motive force generated by complexes III and IV (there is no complex I in S. cere-
visiae). The rate of ATP synthesis was reduced in the atp6-S175N mutant by 90% compared with the WT (Fig. 3B, 
Supplementary Table S4). Since state 3 respiration and ATP synthesis rates were decreased in similar proportions 
in the mutant, it can be inferred that the observed oxidative phosphorylation deficit mostly resulted from a slower 
ATP synthesis rate rather than a less efficient coupling of the mitochondrial energy transducing system.
Though the ATP synthesis activity of ATP synthase was considerably affected by the atp6-S75N mutation, 
its ATP hydrolytic activity was only partially compromised, as evidenced by direct measurements on total mito-
chondrial samples (Supplementary Table S4) and in BN-gels loaded with mitochondrial extracts solubilized with 
digitonin (Fig. 4D, see below). However, while this activity was largely inhibited by oligomycin in the WT, it was 
mostly insensitive to this drug in the mutant, which is frequently observed in yeast FO-deficient mutants14,18,19,23,24.
Mitochondrial membrane potential. The consequences of the atp6-S175N mutation on oxidative phosphoryl-
ation in yeast cells were analysed further using Rhodamine 123. This is a fluorescent cationic dye that can be 
used to monitor changes in the inner membrane potential (Δ Ψ ) on intact mitochondria25. Increasing Δ Ψ is 
followed by the uptake of the dye inside the matrix space and concomitant fluorescence quenching. In a first set of 
experiments (Fig. 4C, upper panel), we tested the capacity of externally added ADP to induce Δ Ψ consumption. 
To this end, the mitochondria were energized first by the respiratory chain, with electrons from ethanol. Due 
to their reduced capacity to respire (Fig. 4B, Supplementary Table S4), atp6-S175N mitochondria were poorly 
energized in comparison to the WT. Normally, further addition of small amounts of ADP induces a transient flu-
orescence increase due to Δ Ψ consumption by the ATP synthase during phosphorylation of the added ADP. This 
was indeed observed in the WT, whereas atp6-S175N mitochondria were virtually insensitive to ADP. KCN was 
then added to inhibit complex IV, which, in WT mitochondria, resulted in a partial Δ Ψ collapse. The remaining 
potential is due to the pumping of protons by the F0 component of ATP synthase coupled to the hydrolysis by its 
F1 sector of the ATP that accumulated in the mitochondrial matrix during phosphorylation of the added ADP. 
Indeed, this potential was lost upon further addition of oligomycin. No oligomycin-sensitive Δ Ψ was observed in 
the mutant mitochondria, which further reflected their strongly reduced capacity to produce ATP.
In another set of experiments, we directly tested the proton-pumping activity of ATP synthase using externally 
added ATP, independently of the respiratory chain (Fig. 4C, bottom panel). The mitochondria were first energized 
Figure 2. Analyses of the mtDNA of the patient. (A) The mtDNAs from the patient and control cells were 
investigated by PCR using two primers from positions 109 to 16364 (16255bp, fragment 1), and 9340 to 8964 
(16250bp, fragment 2), as depicted on the left, and agarose gel analysis of the amplified DNA fragments (right), 
which revealed the absence of deletion in the mtDNA of the patient. (B) Relative mtDNA copy number in the 
patient and control as measured by real-time quantitative PCR. (C) Partial mtDNA sequence chromatogram 
showing the presence at position 8969 in the patient of both the wild type (Guanine (G), in black) and mutant 
(Adenine (A), in green) nucleotides. (D) Percentages of the G8969> A mutation in the blood and urine 
sediments of the patient’s mother, and in urine sediments, blood and kidney of the patient, as determined by 
pyrosequencing.
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Figure 3. Properties of trans-mitochondrial cell lines carrying various proportion of the G8969>A 
mutation. (A) Percentages of the G8969> A mutation in cybrid cell lines. (B) Mitochondrial ultrastructure 
(magnification × 50,000). In C-98, arrows point to aberrant, torus and horseshoe-shape, mitochondria.  
(C) Cellular respiration. The OCR (oxygen consumption rates) were evaluated in cybrids with different levels 
of G8969> A mutation. OSR (oligomycin-sensitive respiration), BR (basal respiration) and MR (maximal 
respiration). *Stands for comparison to WT, # is comparison to C-19. (D) Levels of reactive oxygen species 
(ROS). The levels of ROS were assessed using 2′ ,7′ -dichlorodihydrofluorescein diacetate (DCFH-DA)47. 
Immunofluorescence was visualized by confocal microscopy (left panel) and quantified by flow cytometry and 
expressed as decimal logarithm versus cell number (right panel). WT, control cells; C-19, C-67, and C-98 are 
cybrid cell lines containing 19%, 67% and 98% of the G8969> A mutation, respectively. ρ 0, cells lacking mtDNA.
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Figure 4. Consequences of an equivalent of the G8969>A mutation (atp6-S175N) in yeast. (A) WT and atp6-
S175N mutant yeast cells grown in glucose were serially diluted and spotted onto plates containing glucose or 
glycerol; photographs were taken after 4 days of incubation. (B) Oxygen consumption (state 3) and ATP synthesis 
rates measured with NADH as an electron donor, expressed in % of the WT (see Supplementary Table S4 for 
details). (C) Variations in mitochondrial membrane potential (Δ Ψ ). These experiments were performed using 
Rhodamine 123, a fluorescent cationic dye. Increasing Δ Ψ is followed by the uptake of the dye inside the matrix 
space and concomitant fluorescence quenching. The tracings in the upper panel reveal the capacity of externally 
added ADP to induce Δ Ψ consumption after energization of the mitochondrial inner membrane by the 
respiratory chain (WT in blue, the mutant in red). The tracings in the bottom directly reflect the proton-pumping 
activity of ATP synthase using externally added ATP, after inhibition of the respiratory chain EtOH, ethanol; 
Oligo, oligomycin; Mito, mitochondria. (D) BN-PAGE analysis of mitochondrial protein extracts solubilized 
with 2% digitonin. ATP synthase complexes (V2, dimeric; V1, monomeric) and free F1 particles were visualized 
in-gel by their ATPase activity and by western blotting after transfer onto nitrocellulose using antibodies against 
subunits Atp1p (α -F1) and Atp6p (subunit-6).
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with ethanol to remove the natural inhibitory peptide (IF1) of the F1-ATPase. The mitochondrial membrane 
potential was then collapsed with KCN, and less than one minute later, thus well before IF1 rebinding26, ATP was 
added. Normally, the external ATP is counter-exchanged against ADP present in the matrix by the ADP/ATP 
translocase, which does not require any Δ Ψ , and the ATP can then be hydrolyzed by F1 coupled to FO-mediated 
proton transport out of the matrix. The ATP addition promoted in WT mitochondria a large and stable fluores-
cence quenching of the dye that was reversed upon F0 inhibition with oligomycin, whereas atp6-S175N mito-
chondria were mostly insensitive to ATP, indicating that the mutation inactivates the proton channel of ATP 
synthase.
Assembly/stability of ATP synthase. Blue-Native-Polacrylamide-Gel-Electrophoresis (BN-PAGE) analyses 
of mitochondrial proteins extracted with digitonin revealed that full ATP synthase complexes accumulated in 
atp6-S175N mitochondria as monomeric and dimeric units, although in lesser amounts than in the WT (Fig. 4D). 
The drop in fully assembled ATP synthase (about 50% vs the WT) was less important than the drop (90%) in ATP 
synthesis activity (see above). It can be inferred that the remaining assembled F1F0 complexes are mostly unable 
to produce ATP, indicating that the atp6-S175N mutation blocks the ATP synthase proton channel. Free F1 par-
ticles, almost absent in the WT, were detected in the mutant, which indicates that the atp6-S175N mutation also 
partially compromised the assembly/stability of the F0 component of ATP synthase.
Topological location of the S148 residue of human a-subunit in the inner mitochondrial 
membrane. The a-subunit and a ring of c-subunits are responsible for the transport of protons across the 
membrane domain (F0) of ATP synthase27,28. This transport drives the rotation of the c-ring, which results in 
conformational changes in the catalytic domain (F1) of the enzyme that ultimately promote ATP synthesis. Recent 
cryo-electron microscopy analyses of ATP synthase from mammals, fungi and bacteria have revealed four hori-
zontal membrane-intrinsic-helices (MH) in the a-subunit that run along the c-ring29–31. Based on these highly 
conserved structures, we construct a structural homology model of this 4-helix bundle for the human a-subunit 
(referred to as aMH2–5) in interaction with a c8-ring (Fig. 5B,C)32. At the interface between a-subunit and the 
c-ring, near the middle of the membrane, are two electrically charged residues (aR159 and cE58) that are well 
known to be involved in the transfer of protons mediated by ATP synthase27,28. A hydrophilic cleft on the external 
side of the inner membrane is presumed to enable protons to reach cE58 from the inter membrane space and, 
after a c-ring rotation, the protons are supposed to be released into a second hydrophilic cleft on the matrix side 
of the membrane (Fig. 5B,C)31. The aS148 residue mutated in our patient is in the matrix-localized cleft, near the 
catalytic cE58 residue. Below we discuss the possibility that the aS148 residue helps, through its hydroxyl group, 
the exit of protons from the c-ring int the mitochondrial matrix.
Discussion
Our study reports the case of a patient initially diagnosed with isolated common IgA nephropathy followed by 
brain and muscle problems, a clinical presentation typically observed in mitochondrial cytopathies2,3,33,34. We thus 
came to suspect a possible involvement of mitochondria in the disease process, which was supported by renal 
tissues analyses showing an enhanced fragmentation of the mitochondrial network (Fig. 1D) and diminished 
NADH oxidation and cytochrome c oxidase activities (Fig. 1E), and there was a strong accumulation of lactate in 
cerebrospinal fluid from the patient (Supplementary Fig. S2).
These findings prompt us to sequence the mtDNA of the patient, which revealed a point mutation (G8969> A) 
in the ATP6 gene (Fig. 2). As a result, a serine residue in the a-subunit of ATP synthase, strictly conserved in 
mitochondria and bacteria (Fig. 5A), is replaced by asparagine. The use of cybrid cell lines with a controlled 
nuclear background enabling a proper expression of mitochondrial function provided strong evidence that the 
G8969> A mutation is very detrimental to ATP synthase. Indeed, increasing the mutation load in these cells 
was paralleled by the appearance of abnormal mitochondrial morphologies (Fig. 3B), a reduced rate of oxygen 
consumption (Fig. 3C) and increased production of ROS (Fig. 3D), which are all typical consequences of defects 
in the ATP synthase11,13. Furthermore, we found that in a homoplasmic yeast model of the G8969> A mutation 
(atp6-S175N) ATP synthase proton translocation was very severely compromised. In our structural homology 
model of the human a-subunit/c-ring complex (Fig. 5B), the mutated serine residue in a hydrophilic pocket on 
the matrix side of the membrane that has been proposed to provide a pathway for protons through the F031. This 
suggests that the mutated serine has possibly a role in F0-mediated proton translocation, owing to the presence 
on its lateral side chain of a hydroxyl group that has the potential to exchange protons. However, mutating this 
residue in E. coli (aS199) into alanine, an aliphatic amino acid residue unable to conduct protons, had no apparent 
effects on ATP synthase function35. Thus, aS148 of human a-subunit is likely not an obligate component of the 
ATP synthase proton channel, but affects proton translocation indirectly.
The strong abundance (89%) of the G8969> A mutation in the kidney compared to other tissues from the 
patient (Fig. 3D) is likely the reason why this organ was primarily affected. Indeed, with such a deleterious muta-
tion and only 10% of wild type mtDNA, there is no doubt that the kidney, an organ with high energy demands36, 
was in the patient deprived of enough ATP to function normally. The presence of the same mutation in the 
mtDNA from the mother suggests a maternal inheritance. The lack of symptoms in the mother can be explained 
by a lower content of the mutation, about 60%, which is typically below the threshold at which mtDNA mutations 
become detrimental for human health8. The enhanced production of ROS induced by the G8969> A may also 
contribute to the disease process by damaging cellular constituents and depolarizing the inner mitochondrial 
membrane, which can ultimately lead to apoptosis37,38.
The ATP6 gene has already been implicated in several human disorders, such as the Leigh Syndrome (LS), bilat-
eral striatal lesions of childhood (BSLC), neuropathy ataxia, and retinitis pigmentosa (NARP)11,39,40. The G8969> 
A mutation was recently found in a patient presenting with MLASA, which is a rare mitochondrial disorder 
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characterized by developmental delay, sensorineural hearing loss, epilepsy, agenesis of the corpus callosum, failure 
to thrive and stroke-like episodes41. The present study extends the spectrum of diseases related to the mitochondrial 
ATP6 gene, and provides the first successful discovery of a defined genetic locus contributing to a disease 
that was primarily diagnosed as IgA nephropathy. There is no known case of a mitochondrial cytopathy that 
manifested first as an isolated kidney disorder6. The differences in clinical presentation between the patient 
displaying MLASA and the case reported in our study are most likely due to distinct distributions of the G8969> A 
mutation within cells and tissues.
Immunosuppressive treatment is commonly used in renal diseases, and corticosteroids have been used for 
over 20 years for treating IgA nephropathy. Our patient was therefore treated with steroids while her mito-
chondrial dysfunction was still unknown, and she showed a complete remission. Finsterer J et al.42 did report a 
mitochondriopathy case without kidney impairment, in which high doses of corticosteroids were proven to be 
beneficial by an as-yet-unknown mechanism. Our work further supports that the use of corticosteroids might be 
beneficial against mitochondriopathies, which is an interesting observation.
IgAN is one the most common renal diseases, which is a pattern of glomerular injury defined by the pres-
ence of glomerular IgA deposits in immunofluorescence microscopy with various non-specific histopathological 
lesions43. As such, IgAN is not a disease diagnosis; rather, it is a descriptive term for a certain type of glomerular 
damage. In the absence of family history and whole exome or genome sequencing a direct causation in kidney 
Figure 5. Topological location of the aS148 residue of a-subunit of human ATP synthase in the inner 
mitochondrial membrane. (A) Alignment of a-subunits from mitochondrial and bacterial origins. The 
G8969> A mutation leads to the replacement with asparagine of the evolutionary conserved serine at position 
148 of the human a-subunit. (B,C) Structural homology model of human c8-ring (PDB # 2XND) in complex 
with four helical segments of the a-subunit (aMH2-5), coloured from blue (N-Term) to red (C-Term) viewed 
from the matrix (B) and from the membrane plane (C). The side chain of aS148 residue is shown as sticks, 
the cE58 and aR159 are as spheres. The arrowed line indicates the pathway for protons during ATP synthesis. 
Protons enter and exit the c-ring/a-subunit through hydrophilic clefts in the membrane represented by the grey 
areas surrounded by dashed lines31.
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disease cannot be firmly ascribed to the G8969> A mutation. Even though we cannot preclude that the IgAN 
presentation of our patient possibly involves or is caused by another yet unknown pathogenic factor of nuclear 
DNA origin, we believe that our study is interesting to the field of kidney diseases. Indeed the strong abundance in 
the kidney of the patient of a mtDNA mutation that severely compromises mitochondrial function possibly con-
tributed or aggravated the renal failure. Such a case has not been described before. Based on the findings reported 
in this study, and results obtained with other patients in which a relatively high prevalence of mtDNA mutations 
and mitochondrial morphology defects were observed (manuscript in preparation), we suggest that nephrologists 
should pay more attention on the possible involvement of a mitochondrial dysfunction when evaluating patients 
suffering from kidney problems and report more systematically for the presence/absence of abnormal mitochon-
drial structures when electron microscopy in renal biopsy samples is performed.
Methods
Subjects. We ascertained a female Chinese patient with recurrent kidney disease and multiple systemic dys-
functions through National Clinical Research Center of Kidney Diseases, Jinling Hospital, Nanjing University 
School of Medicine, Nanjing, China. One hundred healthy control adults were recruited from a panel of unaf-
fected, genetically unrelated Han Chinese individuals from the same geographic region. Written informed 
consent was obtained from the patient and her mother as well as the 100 healthy controls. All experimental 
protocols were approved by the Ethics Committee of the Jinling Hospital (Nanjing, China) in accordance with the 
Declaration of Helsinki. All methods and procedures were conducted according to the manufacturers’ instruc-
tions or in strict accordance with the recommendations in the guidelines set forth by the Ethics Committee of the 
Jinling Hospital (Nanjing, China).
Clinical and histological evaluation. Evaluations of the patient were taken using different methods of 
assessment, including medical history, physical examination and laboratory tests (routine urine and blood test) 
every time she visited the clinic. Renal biopsy was performed under ultrasound guidance by an experienced 
investigator, and tissues were processed for light, electron, and immunofluorescence microscopy as described44. 
Electron microscopy examination was conducted with 60–80 nm ultrathin tissue sections fixed in 2.5% glutar-
aldehyde and embedded in epon. Mitochondrial enzyme activity analysis was carried out on frozen renal tissue 
by histochemistry staining for cytochrome c oxidase (COX) and nicotinamide adenine dinucleotide (NADH) 
dehydrogenase as described45.
Mitochondrial genome analyses. Total genomic DNA was isolated from blood, urine sediments and 
renal samples using the QIAamp DNA extraction kit (QIAGEN). The 16.5 kb mtDNA was amplified using 15 
polymerase chain reaction (PCR) primer pairs and then sequenced. The sequencing data were compared against 
the revised Cambridge Reference Sequence (rCRS) of human mtDNA (GenBank NC_012920.1). For detection of 
mtDNA deletion, long range PCR was amplified using two primer pairs and the amplified DNA fragments were 
separated by electrophoresis on a 0.8% agarose gel. Real-time quantitative PCR was used to determine mtDNA 
copy number, relative to the nuclear 18S rRNA gene, using two primers specific of the mitochondrial COX1 locus 
and two primers specific of the nuclear 18SrRNA locus. The Pyromark Q24 platform (Qiagen) was used to assess 
the levels of heteroplasmy of the G8969> A mutation. For this, a fragment around position 8969 was PCR ampli-
fied with two primers firstly; then pyrosequencing of the amplificate was performed using the sequencing primer. 
The presence of the G8969> A mutation was also analyzed in 100 controls. All the primers used in this study were 
listed in Supplementary Table S1.
Transmitochondrial cybrid construction and analyses. Transmitochondrial cybrids were generated 
on a background of HeLa cell line devoid of their own mtDNA (ρ 0 cells, a gift of Professor Bin Lu). Platelets of the 
patient were extracted from 8~10 ml peripheral blood and subsequently fused with ρ 0 cells using 50% (w/v) poly-
ethylene glycol 1500 solution (Fluka) essentially as described46. A series of remarkably stable clones harboring 19%, 
67% and 98% of the G8969A mutant mtDNA were obtained. HeLa cells and cybrids were cultured in Dulbecco’s 
modified Eagle’s medium containing 10% fetal bovine serum and 100 units/ml of penicillin streptomycin. For 
growing ρ 0 cells, the medium was supplemented with sodium pyruvate (110 mg/ml) and uridine (50 mg/ml). 
Electron microscopy analyses were performed using cells fixed with 2.5% (v/v) glutaraldehyde in epon.
Oxygen consumption rates (OCR) were measured using the Seahorse XF96 Extracellular Flux Analyser 
(Seahorse Bioscience, North Billerica, MA, USA). 8.0 × 103 of cybrid cells, HeLa and ρ 0 cells were seeded into 96 
well Seahorse microplates in 80 μ l of growth medium and incubated at 37 °C in 5% CO2 for 24 h and the calibra-
tor plate was equilibrated in a non-CO2 incubator overnight. Basal respiration (BR) corresponds to the drop in 
OCR induced by 1 μ M antimycin. The part of BR insensitive to 1 mM oligomycin corresponds to OSR. Maximal 
respiratory (MR) was induced by uncoupling the mitochondrial membrane 1 μ M proton ionophore carbonylcy-
anide p-trifluoromethoxyphenylhydrazone (FCCP). The levels of ROS production was assessed by staining with 
2′ ,7′ -dichlorodihydrofluorescein diacetate (DCFH-DA) as described47. Immunofluorescence green staining was 
observed under confocal microscopy and fluorescence intensity was measured by flow cytometry (excitation at 
488 nm and emission at 529 nm) and is expressed as decimal logarithm versus cell number.
Construction of the yeast atp6-S175N mutant. The QuikChange XL Site-directed Mutagenesis Kit of 
Stratagene was used to introduce a G8969> A mutation equivalent to the yeast ATP6 gene cloned in pUC1918, 
using the primer 5′ -CCTTTATTAGTTATTATTGAAACTTTAAATTATTTCGCTAGAGCTATTTCATTAGG. 
The mutated (atp6-S175N) gene was cloned into plasmid pJM2 containing the yeast mitochondrial COX2 gene as 
a mitochondrial transformation marker48. The resulting plasmid (pRK66) was introduced by co-transformation 
with the nuclear selectable LEU2 plasmid Yep351 into the ρ 0 strain DFS160 (see Supplementary Table S2 for com-
plete genotype) using the biolistic PDS-1000/He particle delivery system (Bio-Rad). Mitochondrial transformants 
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(RKY104) were identified among the Leu+ clones by their ability to restore respiration when mated to NB40-3C, 
a strain that bears a deletion in the mitochondrial COX2 gene48. They were then crossed to the atp6::ARG8m 
deletion strain MR1018, which produced clones (RKY105) harboring the MR10 nucleus and where the ARG8m 
open reading frame had been replaced with the mutated atp6-S175N gene; these clones were identified as arginine 
prototrophs and their inability to grow on non-fermentable carbon source. DNA sequencing of RKY105 revealed 
no other change in the ATP6 gene than the atp6-S175N mutation.
Biochemical analyses of yeast mitochondria. Mitochondrial enzyme assays and membrane potential 
analyses were performed on mitochondria isolated from yeast cells grown in rich galactose (YPGALA). The 
mitochondria were prepared as described49. Oxygen consumption rates were measured with a Clark electrode 
in 0.65 M mannitol, 0.36 mM EGTA, 5 mM Tris/phosphate, 10 mM Tris/maleate pH 6.8 (respiration buffer), as 
described previously50.
Variations in transmembrane potential (Δ Ψ ) were evaluated in the respiration buffer by measurement 
of rhodamine 123 fluorescence quenching with a Cary Eclipse Fluorescence Spectrophotometer (Agilent 
Technologies, Santa Clara, CA, USA)25,51. For ATP synthesis rate measurements, the mitochondria (0.15 mg/ml) 
were placed in a 1 ml thermostatically controlled chamber at 28 °C in respiration buffer. The reaction was started 
by the addition of 4 mM NADH and 1 mM ADP and stopped by 3.5% perchloric acid, 12.5 mM EDTA. Samples 
were neutralized to pH 6.5 by addition of KOH, 0.3 M MOPS and ATP was quantified by Kinase-Glo Max 
Luminescence Kinase Assays (Promega) on a Beckman Coulter's Paradigm Plate Reader. Part of the ATP pro-
duced by the F1F2-ATP synthase was assessed using oligomycin (20 μ g/mg of proteins).
BN–PAGE analysis was performed as described52. Polyclonal antibodies raised against yeast ATP synthase 
were used after 1:10000 dilution. Nitrocellulose membranes were incubated with peroxidase-labeled antibodies 
at a 1:10000 dilution and revealed with the ECL reagent of Millipore.
Multiple sequence alignment and homology modelling of human ac8 complex. Multiple 
sequence alignment of ATP synthase a-subunit was performed using Clustalw. TMHMM 2.0 and PSIPRED 3.3 
servers were used to predict transmembrane segments and secondary structures, respectively. Figure 5A was 
drawn using the ESPRIPT program. The homology model of human ac8 complex is based on the atomic model 
build in the cryo-electron microscopy density map of the bovine ATP synthase (pdb:5ARH; emdb:3166)29 and the 
bovine c8-ring crystal structure (pdb:2xnd)32. It was built using Phire2, energy minimized using Phenix, Fig. 5B,C 
was drawn using Pymol.
Statistics. Data are expressed as means ± S.D. or S.E.M. SPSS software (16.0), unpaired t test and analysis of 
variance (ANOVA) were used for comparison between groups of data. A p value < 0.05 was considered as statis-
tically significant.
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